Authors:
Wilschanski, M
Famini, H
Strauss-Liviatan, N
Rivlin, J
Blau, H
Bibi, H
Bentur, L
Yahav, Y
Springer, H
Kramer, MR
Klar, A
Ilani, A
Kerem, B
Kerem, E
Citation: M. Wilschanski et al., Nasal potential difference measurements in patients with atypical cystic fibrosis, EUR RESP J, 17(6), 2001, pp. 1208-1215
Authors:
Wilschanski, M
Famini, C
Blau, H
Rivlin, J
Augarten, A
Avital, A
Kerem, B
Kerem, E
Citation: M. Wilschanski et al., A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations, AM J R CRIT, 161(3), 2000, pp. 860-865
Authors:
Nissim-Rafinia, M
Chiba-Falek, O
Sharon, G
Boss, A
Kerem, B
Citation: M. Nissim-rafinia et al., Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations, HUM MOL GEN, 9(12), 2000, pp. 1771-1778
Authors:
Hellman, A
Rahat, A
Scherer, SW
Darvasi, A
Tsui, LP
Kerem, B
Citation: A. Hellman et al., Replication delay along FRA7H, a common fragile site on human chromosome 7, leads to chromosomal instability, MOL CELL B, 20(12), 2000, pp. 4420-4427
Authors:
Abriel, H
Wehrens, XHT
Benhorin, J
Kerem, B
Kass, RS
Citation: H. Abriel et al., Molecular pharmacology of the sodium channel mutation D1790G linked to thelong-QT syndrome, CIRCULATION, 102(8), 2000, pp. 921-925
Authors:
Benhorin, J
Taub, R
Goldmit, M
Kerem, B
Kass, RS
Windman, I
Medina, A
Citation: J. Benhorin et al., Effects of flecainide in patients with new SCN5A mutation - Mutation-specific therapy for long-QT syndrome?, CIRCULATION, 101(14), 2000, pp. 1698-1706
Authors:
Chiba-Falek, O
Parad, RB
Kerem, E
Kerem, B
Citation: O. Chiba-falek et al., Variable levels of normal RNA in different fetal organs carrying a cystic fibrosis transmembrane conductance regulator splicing mutation, AM J R CRIT, 159(6), 1999, pp. 1998-2002